novo direct semaglutide Nordisk gets into the direct-to-patient game with Wegovy Novo Nordisk to sell obesity

Russian clinical trials in generalized anxiety disorder found it comparable to the benzodiazepine medazepam on anxiety scales without producing sedation

Understanding these mechanisms helps explain why this peptide has attracted significant research interest for anti-aging applications

JAMA Dermatol 2013

46.3 0.8 pmol/mg protein

The "minimal initial benefit" group (approximately 5-10% of users) reported limited improvements during treatment making discontinuation effects irrelevant, typically explained by inadequate product quality with degraded or low-concentration GHK-Cu, inappropriate application technique reducing absorption, unrealistic expectations exceeding what any topical can achieve, severe underlying pathology requiring medical intervention beyond cosmetic peptides, or individual non-responsiveness to copper peptide treatment for genetic or physiological reasons